29th Mar 2021 09:17
(Alliance News) - Immunodiagnostic Systems Holdings PLC on Monday said its SARS-CoV-2 test has secured emergency use backing by US health regulators.
The Tyne & Wear-based diagnostic testing kits and instruments maker was trading 16% higher at 220.00 pence each in London on Monday morning. It rose as high as 242.27p earlier.
"The test has received the US Food & Drug Administration's emergency use authorisation. As a result, IDS is now able to sell the test to laboratories in the USA for clinical testing purposes," the company said.
An emergency use authorisation is handed out by the US FDA to help strengthen national efforts during a health emergency.
Immunodiagnostic said the test "does not cross-react with other strains of coronavirus", making it less prone to producing a false positive result.
By Eric Cunha; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
IDH.L